Published in Transplantation on January 15, 1995
Experimental and clinical evidence for modification of hepatic ischaemia-reperfusion injury by N-acetylcysteine during major liver surgery. HPB (Oxford) (2011) 0.89
Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. Proc Natl Acad Sci U S A (2002) 0.84
Mitochondrial Dysfunction and Autophagy in Hepatic Ischemia/Reperfusion Injury. Biomed Res Int (2015) 0.81
Glutathione ethyl ester supplementation during pancreatic islet isolation improves viability and transplant outcomes in a murine marginal islet mass model. PLoS One (2013) 0.80
N-acetylcysteine administration does not improve patient outcome after liver resection. HPB (Oxford) (2013) 0.79
N-acetylcysteine induces shedding of selectins from liver and intestine during orthotopic liver transplantation. Clin Exp Immunol (2001) 0.78
Combined use of N-acetylcysteine and Liberase improves the viability and metabolic function of human hepatocytes isolated from human liver. Cytotherapy (2014) 0.77
A systematic review of neuroprotective strategies after cardiac arrest: from bench to bedside (Part I - Protection via specific pathways). Med Gas Res (2014) 0.77
Beneficial effects of N-acetyl cysteine on pancreas and kidney following experimental pancreatic ischemia-reperfusion in rats. Clinics (Sao Paulo) (2010) 0.76
The use of N-acetylcysteine in solid-organ preservation solutions. Transplantation (1996) 0.75
Kinetic analysis of secretory protein traffic and characterization of golgi to plasma membrane transport intermediates in living cells. J Cell Biol (1998) 5.14
Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem J (1998) 2.65
CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res (1996) 2.18
Effects of charged amino acid mutations on the bimolecular kinetics of reduction of yeast iso-1-ferricytochrome c by bovine ferrocytochrome b5. Biochemistry (1993) 2.14
Ivermectin-resistant Ostertagia circumcincta from sheep in the lower North Island and their susceptibility to other macrocyclic lactone anthelmintics. N Z Vet J (2000) 2.07
Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett (1998) 1.96
Investigating neural primacy in Major Depressive Disorder: multivariate Granger causality analysis of resting-state fMRI time-series data. Mol Psychiatry (2010) 1.83
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant (2010) 1.67
Expanded indications for laser-assisted balloon angioplasty in peripheral arterial disease. J Vasc Surg (1990) 1.62
Hepatocyte growth factor: a multifunctional cytokine. Lancet (1995) 1.61
One hundred nine living donor liver transplants in adults and children: a single-center experience. Ann Surg (2001) 1.61
Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol (2000) 1.59
Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol (1997) 1.55
Interaction-induced shift of the cyclotron resonance of graphene using infrared spectroscopy. Phys Rev Lett (2010) 1.51
Brucella infection with pancytopenia after pediatric liver transplantation. Transpl Infect Dis (2012) 1.45
Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. Liver Transpl (2001) 1.44
The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr (2001) 1.43
Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology (1996) 1.42
Reassessing the role of medical therapy in the management of hepatic vein thrombosis. Liver Transpl Surg (1997) 1.41
Use of the superficial femoral vein as a replacement for large veins. J Vasc Surg (1991) 1.40
Outcome for patients treated with laparoscopic versus open resection of hepatocellular carcinoma: case-matched analysis. Ann Surg Oncol (2009) 1.34
Central nervous system complications in liver transplant recipients--incidence, timing, and long-term follow-up. Clin Transplant (2000) 1.34
A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg (1995) 1.32
Hepatic epithelioid hemangioendothelioma: resection or transplantation, which and when? Liver Transpl Surg (1999) 1.32
Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol (2000) 1.30
ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene (1997) 1.28
Etiology of chronic renal failure in Turkish children. Pediatr Nephrol (1995) 1.27
Maternal transmission of immunity to Eimeria maxima: enzyme-linked immunosorbent assay analysis of protective antibodies induced by infection. Infect Immun (1994) 1.25
Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol (2000) 1.19
Safety and risk of using pediatric donor livers in adult liver transplantation. Liver Transpl (2001) 1.17
Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology (1995) 1.16
Liver transplantation for autoimmune hepatitis. Hepatology (2000) 1.16
Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis (1996) 1.16
Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant (2007) 1.13
The molecular genetic analysis of the expanding pachyonychia congenita case collection. Br J Dermatol (2014) 1.13
Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation (2000) 1.12
Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg (1998) 1.11
Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant (2013) 1.11
Safe use of hepatic allografts from donors older than 70 years. Transplantation (1996) 1.09
False aneurysm of the hepatic artery after laparoscopic cholecystectomy. Acta Chir Belg (2002) 1.08
Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation (2001) 1.08
A pilot study of posttraumatic stress and nonadherence in pediatric liver transplant recipients. Pediatrics (2000) 1.07
Neonatal hemochromatosis: the importance of early recognition of liver failure. J Pediatr (2000) 1.07
Endovascular treatment of arteriovenous fistulas complicating percutaneous renal biopsy in three paediatric cases. Nephrol Dial Transplant (1999) 1.06
Long-term results of surgery for liver hemangiomas. Arch Surg (2000) 1.06
Liver resection under total vascular isolation. Variations on a theme. Ann Surg (1993) 1.06
Eimeria maxima gametocyte antigens: potential use in a subunit maternal vaccine against coccidiosis in chickens. Vaccine (1995) 1.05
FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. Transplantation (1995) 1.05
Accuracy and significance of computed tomographic scan assessment of hepatic volume in patients undergoing liver transplantation. Transplantation (2000) 1.04
Infrared spectroscopy of Landau levels of graphene. Phys Rev Lett (2007) 1.03
The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology (1998) 1.03
Improving adherence to medications in pediatric liver transplant recipients. Pediatr Transplant (2008) 1.03
A binding site for activation by the Bacillus subtilis AhrC protein, a repressor/activator of arginine metabolism. Mol Gen Genet (1995) 1.03
Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? Eur J Surg Oncol (2007) 1.02
A simple new formula to assess liver weight. Transplant Proc (2003) 0.98
Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther (2001) 0.98
Adult living donor liver transplantation: the hepatologist's perspective. Hepatology (2001) 0.98
Non-adherence in pediatric liver transplant recipients--an assessment of risk factors and natural history. Pediatr Transplant (2000) 0.98
Use of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. Am J Transplant (2010) 0.98
Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: implications for genotoxicity testing. Mutat Res (1999) 0.98
Dissecting the molecular details of prokaryotic transcriptional control by surface plasmon resonance: the methionine and arginine repressor proteins. Biosens Bioelectron (1998) 0.98
Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer (1998) 0.97
Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop. Mol Vis (2010) 0.97
Living related liver transplantation for acute liver failure in children. Liver Transpl Surg (1999) 0.97
Selective modulation of T cell memory markers CD62L and CD44 on murine draining lymph node cells following allergen and irritant treatment. Toxicol Appl Pharmacol (1997) 0.96
Renal allograft survival in outbred mongrel dogs using rabbit anti-dog thymocyte serum in combination with immunosuppressive drug therapy with or without donor bone marrow. Vet Surg (1995) 0.95
Two new loci for autosomal recessive ichthyosis on chromosomes 3p21 and 19p12-q12 and evidence for further genetic heterogeneity. Am J Hum Genet (2000) 0.95
Late mortality and morbidity after liver transplantation. Transplant Proc (1987) 0.95
Combined hepatic and vena caval resection with autogenous caval graft replacement. Arch Surg (1991) 0.94